This places Retatrutide among the most potent pharmacological weight management agents studied to date
Studies demonstrate that postmenopausal women on hormone therapy achieve 30% greater weight loss with semaglutide compared to those not using hormones.[3] The mechanism involves estrogen's ability to increase GLP-1R expression in the brain, particularly during high estrogen phases, and enhance the downstream signaling cascades activated by GLP-1
Therapeutic strategies include induced lipid peroxidation, adjustment of iron homeostasis, increase of PUFA bioavailability and combination of ferroptosis promoting agents with conventional treatments
Jahan S, Abid A, Khalid S, Afsar T, Ain QU, Shaheen G, et al
Information about ongoing trials can be found via the ISRCTN registry (isrctn.com) and ClinicalTrials.gov